Literature DB >> 22015770

Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases.

C Haferlach, V Grossmann, A Kohlmann, S Schindela, W Kern, S Schnittger, T Haferlach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22015770     DOI： 10.1038/leu.2011.296

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

2.  Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Authors:  Moriah H Nissan; Christine A Pratilas; Alexis M Jones; Ricardo Ramirez; Helen Won; Cailian Liu; Shakuntala Tiwari; Li Kong; Aphrothiti J Hanrahan; Zhan Yao; Taha Merghoub; Antoni Ribas; Paul B Chapman; Rona Yaeger; Barry S Taylor; Nikolaus Schultz; Michael F Berger; Neal Rosen; David B Solit
Journal:  Cancer Res       Date:  2014-02-27       Impact factor: 12.701

Review 3.  Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.

Authors:  Katerina Zoi; Nicholas C P Cross
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

4.  An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Nicholas C P Cross; Eric Padron; Ramon V Tiu; Michael Savona; Luca Malcovati; Raoul Tibes; Rami S Komrokji; Jean-Jacques Kiladjian; Guillermo Garcia-Manero; Attilio Orazi; Ruben Mesa; Jaroslaw P Maciejewski; Pierre Fenaux; Raphael Itzykson; Ghulam Mufti; Eric Solary; Alan F List
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

Review 5.  Myeloid malignancies: mutations, models and management.

Authors:  Anne Murati; Mandy Brecqueville; Raynier Devillier; Marie-Joelle Mozziconacci; Véronique Gelsi-Boyer; Daniel Birnbaum
Journal:  BMC Cancer       Date:  2012-07-23       Impact factor: 4.430

Review 6.  Neurofibromin and suppression of tumorigenesis: beyond the GAP.

Authors:  Juan Mo; Stefanie L Moye; Renee M McKay; Lu Q Le
Journal:  Oncogene       Date:  2022-01-23       Impact factor: 8.756

7.  Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.

Authors:  Joseph A Clara; David A Sallman; Eric Padron
Journal:  Cancer Biol Med       Date:  2016-09       Impact factor: 4.248

8.  Integration of SNP and mRNA arrays with microRNA profiling reveals that MiR-370 is upregulated and targets NF1 in acute myeloid leukemia.

Authors:  Laura García-Ortí; Ion Cristóbal; Cristina Cirauqui; Elisabet Guruceaga; Nerea Marcotegui; María J Calasanz; Remedios Castello-Cros; María D Odero
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

Review 9.  Non-heritable genetics of human disease: spotlight on post-zygotic genetic variation acquired during lifetime.

Authors:  Lars Anders Forsberg; Devin Absher; Jan Piotr Dumanski
Journal:  J Med Genet       Date:  2012-11-21       Impact factor: 6.318

10.  Republished: Non-heritable genetics of human disease: spotlight on post-zygotic genetic variation acquired during lifetime.

Authors:  Lars Anders Forsberg; Devin Absher; Jan Piotr Dumanski
Journal:  Postgrad Med J       Date:  2013-07       Impact factor: 2.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.